SCHEMBL12237103

SCHEMBL12237103

CC(C)(C)OC(=O)[C@@H]1C[C@H](O)CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)C1CCCCC1)C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 2/20 0.47
CASP1 P29466 1/20 0.43
CASP3 P42574 1/20 0.43
CASP2 P42575 1/20 0.43
CASP4 P49662 1/20 0.43
CASP5 P51878 1/20 0.43
CASP7 P55210 1/20 0.43
CASP9 P55211 1/20 0.43
CASP8 Q14790 1/20 0.43
CASP10 Q92851 1/20 0.43
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
ADORA1 P30542 1/20 0.42
ELANE P08246 1/20 0.42
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39
FKBP1A P62942 1/20 0.39
CTSB P07858 1/20 0.38
CTSS P25774 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12237104 0.89 CTSL (0.47) CTSLCASP1CASP3CASP2CASP4
SCHEMBL3051904 0.85 CTSL (0.46) CTSLCASP1CASP3CASP2CASP4
SCHEMBL13245760 0.85 CTSL (0.46) CTSLCASP1CASP3CASP2CASP4
SCHEMBL21933413 0.83 CTSL (0.53) CTSLELANESYK
SCHEMBL28623023 0.83 CTSL (0.53) CTSLELANESYK
SCHEMBL2326116 0.83 CTSL (0.48) CTSLCASP1CASP3CASP2CASP4
SCHEMBL2326113 0.83 CTSL (0.48) CTSLCASP1CASP3CASP2CASP4
SCHEMBL2326118 0.83 CTSL (0.48) CTSLCASP1CASP3CASP2CASP4
SCHEMBL34471517 0.82 CTSL (0.55) CTSLITGB3ITGA2BFKBP1APREP
SCHEMBL8292178 0.82 ALDH1A1 (0.47) ELANEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039623-B2 Peptidomimetics compound; viricides; interference in life cycle og hepatitis c virus VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-10-18 US disclosed
US-20070161789-A1 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED 2007-07-12 US disclosed
US-7208600-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161789-A1 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease PRSS1, SERPINB1, SPINT2 CTSL 28/4885CASP1 214/4885CASP3 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.